Michael R. DiGruccio

Michael R. DiGruccio

Auto-generated profile, based on publicly available information

Michael R. DiGruccio

Department of Anesthesiology, Neuroscience Graduate Program

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CGChristy R. R. Grace
Christy R. R. Grace
MPMarilyn H. Perrin
Marilyn H. Perrin
MDMichael R. DiGruccio
Michael R. DiGruccio
CMCharleen L. Miller
Charleen L. Miller
JRJean E. Rivier
Jean E. Rivier
RRRoland Riek
Roland Riek
The corticotropin-releasing factor (CRF) ligand family has diverse effects on the CNS, including the modulation of the stress response. The ligands' effects are mediated by binding to CRF G protein-coupled receptors. We have determined the 3D NMR structure of the N-terminal extracellular domain (ECD 1 ) of the mouse CRF receptor 2β, which is the major ligand recognition domain, and identified its ligand binding site by chemical-shift perturbation experiments. The fold is identified as a short consensus repeat (SCR), a common protein interaction module. Mutagenesis reveals the integrity of the hormone-binding site in the full-length receptor. This study proposes that the ECD 1 captures the C-terminal segment of the ligand, whose N terminus then penetrates into the transmembrane region of the receptor to initiate signaling. Key residues of SCR in the ECD 1 are conserved in the G protein-coupled receptor subfamily, suggesting the SCR fold in all of the ECD 1 s of this subfamily.

1 March 2012 in Neurobiology of Disease
Verified
Journal Article
Closed access
ABAnnalisa Boscolo
Annalisa Boscolo
JSJ.A. Starr
J.A. Starr
VSV. Sanchez
V. Sanchez
NLN. Lunardi
N. Lunardi
MDM.R. DiGruccio
M.R. DiGruccio
VJV. Jevtovic-Todorovic
V. Jevtovic-Todorovic

12 September 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JRJ. Rivier
J. Rivier
JGJ. Gulyas
J. Gulyas
DKD. Kirby
D. Kirby
WLW. Low
W. Low
MPM. H. Perrin
M. H. Perrin
WVW. Vale
W. Vale

20 March 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CGChristy Rani R. Grace
Christy Rani R. Grace
MPMarilyn H. Perrin
Marilyn H. Perrin
JGJozsef Gulyas
Jozsef Gulyas
MDMichael R. DiGruccio
Michael R. DiGruccio
JCJeffrey P. Cantle
Jeffrey P. Cantle
RRRoland Riek
Roland Riek
The corticotropin releasing factor (CRF) family of ligands and their receptors coordinate endocrine, behavioral, autonomic, and metabolic responses to stress and play additional roles within the cardiovascular, gastrointestinal, and other systems. The actions of CRF and the related urocortins are mediated by activation of two receptors, CRF-R1 and CRF-R2, belonging to the B1 family of G protein-coupled receptors. The short-consensus-repeat fold (SCR) within the first extracellular domain (ECD1) of the CRF receptor(s) comprises the major ligand binding site and serves to dock a peptide ligand via its C-terminal segment, thus positioning the N-terminal segment to interact with the receptor's juxtamembrane domains to activate the receptor. Here we present the 3D NMR structure of ECD1 of CRF-R2β in complex with astressin, a peptide antagonist. In the structure of the complex the C-terminal segment of astressin forms an amphipathic helix, whose entire hydrophobic face interacts with the short-consensus-repeat motif, covering a large intermolecular interface. In addition, the complex is characterized by intermolecular hydrogen bonds and a salt bridge. These interactions are quantitatively weighted by an analysis of the effects on the full-length receptor affinities using an Ala scan of CRF. These structural studies identify the major determinants for CRF ligand specificity and selectivity and support a two-step model for receptor activation. Furthermore, because of a proposed conservation of the fold for both the ECD1s and ligands, this structure can serve as a model for ligand recognition for the entire B1 receptor family.

18 October 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
POPeihan Orestes
Peihan Orestes
HOHari Prasad Osuru
Hari Prasad Osuru
WMWilliam E. McIntire
William E. McIntire
MJMegan O. Jacus
Megan O. Jacus
RSReza Salajegheh
Reza Salajegheh
STSlobodan M. Todorovic
Slobodan M. Todorovic
It has been established that CaV3.2 T-type voltage-gated calcium channels (T-channels) play a key role in the sensitized (hyperexcitable) state of nociceptive sensory neurons (nociceptors) in response to hyperglycemia associated with diabetes, which in turn can be a basis for painful symptoms of peripheral diabetic neuropathy (PDN). Unfortunately, current treatment for painful PDN has been limited by nonspecific systemic drugs with significant side effects or potential for abuse. We studied in vitro and in vivo mechanisms of plasticity of CaV3.2 T-channel in a leptin-deficient (ob/ob) mouse model of PDN. We demonstrate that posttranslational glycosylation of specific extracellular asparagine residues in CaV3.2 channels accelerates current kinetics, increases current density, and augments channel membrane expression. Importantly, deglycosylation treatment with neuraminidase inhibits native T-currents in nociceptors and in so doing completely and selectively reverses hyperalgesia in diabetic ob/ob mice without altering baseline pain responses in healthy mice. Our study describes a new mechanism for the regulation of CaV3.2 activity and suggests that modulating the glycosylation state of T-channels in nociceptors may provide a way to suppress peripheral sensitization. Understanding the details of this regulatory pathway could facilitate the development of novel specific therapies for the treatment of painful PDN.

8 February 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ACAlon M. Chen
Alon M. Chen
MPMarilyn H. Perrin
Marilyn H. Perrin
MDMichael R. DiGruccio
Michael R. DiGruccio
JVJoan M. Vaughan
Joan M. Vaughan
BBBhawanjit K. Brar
Bhawanjit K. Brar
WVWylie W. Vale
Wylie W. Vale
Peptides of the corticotropin-releasing factor (CRF) family signal through the activation of two receptors, CRF receptor type 1 (CRFR1) and type 2 (CRFR2), both of which exist as multiple splice variants. We have identified a cDNA from mouse brain encoding a splice variant, soluble CRFR2α (sCRFR2α), in which exon 6 is deleted from the gene encoding CRFR2α. Translation of this isoform produces a predicted 143-aa soluble protein. The translated protein includes a majority of the first extracellular domain of the CRFR2α followed by a unique 38-aa hydrophilic C terminus resulting from a frame shift produced by deletion of exon 6. By using RT-PCR and Southern hybridization, the relative mRNA expression levels of full-length (seven transmembrane domains) CRFR2α and the soluble form (sCRFR2α) in the mouse brain were measured with a single reaction. The results demonstrate high levels of expression of sCRFR2α in the olfactory bulb, cortex, and midbrain regions. A rabbit antiserum raised against a synthetic peptide fragment encoding the unique C terminus revealed specific sCRFR2α immunoreactivity in mouse brain slices by immunohistochemistry and in extracts of brain regions by RIA. Interestingly, the sCRFR2α immunoreactivity distribution closely approximated that of CRFR1 expression in rodent brain. A protein corresponding to sCRFR2α, expressed and purified from either mammalian or bacterial cell systems, binds several CRF family ligands with low nanomolar affinities. Furthermore, the purified sCRFR2α protein inhibits cellular responses to CRF and urocortin 1. These data support a potential role of the sCRFR2α protein as a possible biological modulator of CRF family ligands.